Andrew Coveler, MD

home / authors / andrew-coveler-md

Articles

Andrew Coveler, MD

Dr. Coveler on Replacing 5-FU With NUC-3373 in mCRC

Andrew Coveler, MD
May 14th 2021

Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.

Read More

Andrew Coveler, MD

Dr. Coveler on the Toxicity Profile of NUC-3373 in Metastatic CRC

Andrew Coveler, MD
April 13th 2021

Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.

Read More

Andrew Coveler, MD, of Seattle Cancer Care Alliance

Dr. Coveler on the Rationale to Evaluate NUC-3373 in Metastatic CRC

Andrew Coveler, MD
February 12th 2021

Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.

Read More

Dr. Coveler on SEA-CD40 Combo in Metastatic Pancreatic Ductal Adenocarcinoma

Dr. Coveler on SEA-CD40 Combo in Metastatic Pancreatic Ductal Adenocarcinoma

Andrew Coveler, MD
June 16th 2020

Andrew Coveler, MD, discusses the investigational CD40-directed monoclonal antibody SEA-CD40 in combination with gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data